Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology
NEW YORK — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced today it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for its proprietary hemostatic gel technology. This follows Cresilon’s successful launch of VETIGEL®, its revolutionary hemostatic gel for the animal health market. …
Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology Read More »
